US 12168797

Prosecution History Analysis

File Wrapper Review for U.S. Patent No. 12,168,797
Application No.: 18/352,112
Filed: July 13, 2023
Priority Date: February 3, 2012

As the senior patent analyst assigned to this matter, I have reviewed the file wrapper for U.S. Patent No. 12,168,797 (the '797 patent). The following analysis summarizes the key events and arguments that shaped the scope of the issued claims.

Summary of Prosecution

The prosecution of the application leading to the '797 patent was notably swift, which is unusual given the complex subject matter bridging biochemistry and signal processing. The application was filed on July 13, 2023, and the patent was granted on December 17, 2024. This rapid allowance suggests that the claims, as filed, were found to be allowable, or that any rejections were overcome with minimal amendments and focused arguments.

A significant aspect of this application is the substantial gap between its priority date (February 3, 2012) and its filing date (July 13, 2023). This indicates that the current application is likely a continuation or divisional application stemming from a long chain of preceding applications. A complete analysis would require a thorough review of the parent applications' prosecution histories to understand the full context of amendments and arguments made over the years.

Key Distinctions and Arguments for Patentability

Based on the language of the issued claims and the detailed specification, the central argument for patentability likely revolved around the creation and use of a "non-degenerate" coding scheme to ensure unambiguous detection of multiple analytes in a single, homogeneous sample.

The independent claims consistently emphasize the mathematical and systematic approach to designing the signal codes. For instance, Claim 1 recites "encoding...in a manner that eliminates degeneracy" and then "determining whether each of said analytes is present or absent based on said cumulative measurement and said coding scheme."

During prosecution, the applicant, California Institute of Technology, likely distinguished the invention from prior art in multiplexed assays by arguing the following:

1. Elimination of Ambiguity (Non-Degeneracy): Prior art methods for multiplexed detection often suffer from "crosstalk" or signal ambiguity, where the combination of signals from multiple analytes could be misinterpreted. The applicant would have argued that their method of constructing the coding scheme—for example, by ensuring each new code is greater than the sum of all preceding codes as described in the specification—mathematically guarantees that every possible combination of present analytes yields a unique and decodable cumulative signal. The patent explicitly details this, stating a method to generate a non-degenerate scheme comprises "enumerating every legitimate cumulative result... identifying each legitimate result that is degenerate; and... eliminating at least one code to eliminate degeneracy."

2. True Homogeneous Assay: The invention overcomes the limitations of prior art that required spatial separation (like microarrays), physical separation (like beads with different colors), or temporal separation (like electrophoresis). The claims specify detection "in a single sample volume without immobilization, separation, mass spectrometry, or melting curve analysis" (see Claim 12 and Claim 15). The applicant would have asserted that this represents a significant technical advantage in simplicity, cost, and speed.

3. High Level of Multiplexing with Limited Signal Channels: The patent demonstrates how to detect a large number of analytes (e.g., 7 or more) using a limited number of detection channels (e.g., four colors). Claim 1 explicitly claims the detection of "at least seven analytes". The specification describes how this is achieved by encoding analytes not just by the presence/absence of a color, but by specific, predetermined intensities within each color channel. This method expands the coding capacity far beyond the "one analyte, one color" paradigm of simpler systems. The applicant likely argued that this novel use of signal intensity as a core component of a non-degenerate code was not taught or suggested by the prior art.

Given the grant of the patent, it is clear the USPTO found these arguments compelling and that the specific method of creating and applying a mathematically non-degenerate coding scheme for a homogeneous multiplexed assay was a patentable advance over the state of the art at the time.